Atlas Trials

A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

Clinical trial NCT05139680 · COMPLETED

Trial details

NCT number
NCT05139680
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
Start date
2023-03-08
Primary completion
2023-05-19
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.